Holmes, he said, chalked up the inaccuracies to quality control and assurance rather than its analyzer’s instrument failure. According to CNBC, Das testified that in 2015 he informed Holmes of a prostate-specific antigen test that was showing inaccuracies. One example the government can revisit to show Holmes’ level of awareness is testimony from former Theranos lab director, Kingshuk Das. Holmes knew Theranos’ technology was faulty but promoted it anyway: prosecutors
#Elizabeth holmes today show april 18 trial
He faces the same charges and is scheduled to stand trial next year. She was indicted back in 2018 after Theranos imploded under regulatory scrutiny, along with Theranos COO and her onetime boyfriend, Sunny Balwani. Holmes is defending 11 counts of fraud and conspiracy for allegedly misrepresenting the viability of Theranos’ blood-testing technology to investors and paying customers.
“That evidence will be used by the government to argue that Holmes had criminal intent when she made statements to investors and to paying patients.” “The evidence produced at trial - both the documents and the testimony of witnesses - supported the claim that Holmes was aware of problems with the technology, and with the financial health of the company,” Roth tells Yahoo Finance. After the defense rests, prosecutors will have a final opportunity to address the jury.Ĭardozo Law School professor Jessica Roth says she expects the government during closing to reinforce that Holmes, as CEO, many times proclaimed herself responsible for everything that happened at the company and as someone who was aware of its shortcomings. Then, the defense team will make their case for their client, who claims she never intentionally deceived anybody by suggesting her startup, Theranos, could perform hundreds of diagnostic tests with just a few drops of blood. Prosecutors will get the first opportunity to make their final arguments. Closing arguments are scheduled to begin today in the trial of Elizabeth Holmes, who could go to prison for as long as 20 years if she's convicted of defrauding patients and investors in her blood-testing startup.